SpliceBio

Cell and gene therapy
#AAV #Financing #Gene therapy #Genetic diseases #Ophthalmology #SpliceBio

SpliceBio secures $135m to advance gene therapy candidates

SpliceBio has closed a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventures.  There was also participation from Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys… Read More

#Business & Investment #News

Rare Disease Day
#Biomedical research #Connecta #iOnctura #Rare disease #Rare Disease Day #SpliceBio

Rare Disease Day 2025: Q&A with industry experts

Rare Disease Day is an observance held on the last day of February annually to raise awareness for rare diseases and improve access to treatment and medical representation for individuals with rare diseases and their families. To mark Rare Disease Day 2025, DDW gathered insight from a range of industry… Read More

#Business & Investment #Exclusive Content #Opinion

FDA
#Clinical trial #Drug discovery #FDA #Regulatory #SpliceBio #Stargardt disease

First-ever FDA IND for a protein splicing gene therapy

The US Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for SpliceBio’s lead programme SB-007, a clinical-stage therapeutic addressing the root genetic cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations. The SpliceBio study uses protein splicing to address… Read More

#News #Regulatory #Trending News